Stock DNA
Pharmaceuticals & Biotechnology
VND 2,932,597 Million (Small Cap)
50.00
NA
0.00%
0.26
2.36%
1.96
Revenue and Profits:
Net Sales:
340,017 Million
(Quarterly Results - Mar 2025)
Net Profit:
25,157 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
56.45%
0%
56.45%
6 Months
49.44%
0%
49.44%
1 Year
46.17%
0%
46.17%
2 Years
76.43%
0%
76.43%
3 Years
70.79%
0%
70.79%
4 Years
2.96%
0%
2.96%
5 Years
100.25%
0%
100.25%
Cuu Long Pharmaceutical JSC for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
16.25%
EBIT Growth (5y)
10.79%
EBIT to Interest (avg)
2.58
Debt to EBITDA (avg)
0.80
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
0.59
Tax Ratio
23.88%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.46%
ROE (avg)
6.63%
Valuation key factors
Factor
Value
P/E Ratio
50
Industry P/E
Price to Book Value
1.43
EV to EBIT
39.07
EV to EBITDA
23.58
EV to Capital Employed
1.32
EV to Sales
1.90
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3.38%
ROE (Latest)
2.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY
Mar'25
Mar'24
Change(%)
Net Sales
340,016.70
277,940.30
22.33%
Operating Profit (PBDIT) excl Other Income
55,503.20
42,801.60
29.68%
Interest
10,129.10
7,008.00
44.54%
Exceptional Items
0.00
0.00
Consolidate Net Profit
25,156.80
22,286.30
12.88%
Operating Profit Margin (Excl OI)
127.50%
119.50%
0.80%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2025 is 22.33% vs 17.38% in Mar 2024
Consolidated Net Profit
YoY Growth in quarter ended Mar 2025 is 12.88% vs 51.85% in Mar 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,306,797.40
1,143,946.30
14.24%
Operating Profit (PBDIT) excl Other Income
98,087.70
109,004.10
-10.01%
Interest
25,494.50
30,530.50
-16.49%
Exceptional Items
0.00
0.00
Consolidate Net Profit
54,145.50
62,134.40
-12.86%
Operating Profit Margin (Excl OI)
45.80%
61.80%
-1.60%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 14.24% vs 12.63% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -12.86% vs -44.97% in Dec 2023
About Cuu Long Pharmaceutical JSC 
Cuu Long Pharmaceutical JSC
Pharmaceuticals & Biotechnology
Cuu Long Pharmaceutical Joint Stock Corporation (Pharimexco) is a Vietnam-based company engaged in the pharmaceutical industry. The Company manufactures, markets and distributes pharmaceutical drugs and capsules, as well as medical equipment and supplies. It is also involved in the manufacture and trading of functional food, cosmetic products, chemicals and other materials for pharmaceutical production. Other activities include the manufacture of specialized packagings for drugs and medical products, as well as the cultivation of traditional herbs.
Company Coordinates 
Company Details
So 150 duong 14/9, phuong 5 , VINH LONG None : None
Registrar Details






